IN2014DN08830A - - Google Patents

Download PDF

Info

Publication number
IN2014DN08830A
IN2014DN08830A IN8830DEN2014A IN2014DN08830A IN 2014DN08830 A IN2014DN08830 A IN 2014DN08830A IN 8830DEN2014 A IN8830DEN2014 A IN 8830DEN2014A IN 2014DN08830 A IN2014DN08830 A IN 2014DN08830A
Authority
IN
India
Prior art keywords
eliciting
immune response
compositions
useful
individual
Prior art date
Application number
Inventor
Richard C Duke
Alex Franzusoff
Aurelia Haller
Thomas H King
Yingnian Lu
Victoria Kelley Hodson
Original Assignee
Globeimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Globeimmune Inc filed Critical Globeimmune Inc
Publication of IN2014DN08830A publication Critical patent/IN2014DN08830A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16311—Influenzavirus C, i.e. influenza C virus
    • C12N2760/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The invention provided herein relates to vaccines that can be tailored to achieve a desired immune response. Some compositions provided herein are used for preferentially eliciting a humoral immune response while other compositions are useful for preferentially eliciting a cell-mediated response. Combinations of vaccine compositions are also useful for eliciting both types of responses and/or for modulating the type of immune response elicited. The invention also provides methods for eliciting an immune response in an individual by administering the compositions disclosed herein. These immune responses are useful for protecting an individual from various types of diseases, infections, and undesirable conditions.
IN8830DEN2014 2006-02-02 2007-02-02 IN2014DN08830A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US76502506P 2006-02-02 2006-02-02
PCT/US2007/061572 WO2007092792A2 (en) 2006-02-02 2007-02-02 Yeast-based vaccine for inducing an immune response

Publications (1)

Publication Number Publication Date
IN2014DN08830A true IN2014DN08830A (en) 2015-07-10

Family

ID=38345897

Family Applications (1)

Application Number Title Priority Date Filing Date
IN8830DEN2014 IN2014DN08830A (en) 2006-02-02 2007-02-02

Country Status (14)

Country Link
US (2) US7736642B2 (en)
EP (2) EP2468296A3 (en)
JP (3) JP5198290B2 (en)
KR (2) KR101492524B1 (en)
CN (2) CN101405026B (en)
AU (1) AU2007212076B2 (en)
BR (1) BRPI0706913A2 (en)
CA (1) CA2638815A1 (en)
IL (2) IL193196A (en)
IN (1) IN2014DN08830A (en)
MX (1) MX2008009929A (en)
SG (2) SG10201402236VA (en)
TW (2) TW201412329A (en)
WO (1) WO2007092792A2 (en)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002039951A2 (en) * 2000-11-15 2002-05-23 Globe Immune, Inc. Yeast-dentritic cell vaccines and uses thereof
US8343502B2 (en) * 2002-12-16 2013-01-01 Globeimmune, Inc. Yeast-based vaccines as immunotherapy
KR101241272B1 (en) * 2002-12-16 2013-03-15 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 Yeast-based vaccines as immunotherapy
BRPI0613025A2 (en) * 2005-07-11 2010-12-14 Globeimmune Inc composition for reducing resistance to an agent, method for preparing a yeast vehicle and use of the composition
US20070172503A1 (en) 2005-12-13 2007-07-26 Mycologics,Inc. Compositions and Methods to Elicit Immune Responses Against Pathogenic Organisms Using Yeast Based Vaccines
CN101405026B (en) * 2006-02-02 2015-04-22 全球免疫股份有限公司 Yeast-based vaccine for inducing an immune response
GB0613977D0 (en) 2006-02-07 2006-08-23 Peptcell Ltd Peptide sequences and compositions
US9101578B2 (en) * 2006-05-01 2015-08-11 Technovax, Inc. Polyvalent influenza virus-like particle (VLP) compositions
WO2008054535A2 (en) * 2006-05-11 2008-05-08 Novavax, Inc. Novel influenza m2 vaccines
CA2657849A1 (en) * 2006-05-18 2008-05-08 Pharmexa Inc. Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions
CN104120086A (en) * 2007-02-02 2014-10-29 环球免疫公司 Method for producing yeast-based vaccines
JP5579451B2 (en) * 2007-03-19 2014-08-27 グローブイミューン，インコーポレイテッド Composition for targeted ablation of avoidance of variability in targeted therapy for cancer
GB0719526D0 (en) * 2007-10-05 2007-11-14 Isis Innovation Compositions and methods
US20100285050A1 (en) 2007-10-05 2010-11-11 Isis Innovation Limited Compositions and Methods
WO2010036948A2 (en) * 2008-09-26 2010-04-01 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Dna prime/inactivated vaccine boost immunization to influenza virus
CN102458458B (en) 2009-04-17 2016-11-16 全球免疫股份有限公司 Combination immunotherapy compositions against cancer and method
KR20120096874A (en) * 2009-05-18 2012-08-31 파나세아 바이오테크 리미티드 Universal influenza vaccine based on recombinant modified vaccinia ankara virus
CA2774326C (en) 2009-09-14 2023-11-07 Donald Bellgrau Modulation of yeast-based immunotherapy products and responses
WO2012006561A2 (en) * 2010-07-08 2012-01-12 New York Medical College Influenza virus detection and diagnosis
AU2011312178B2 (en) * 2010-10-04 2016-05-12 Massachusetts Institute Of Technology Hemagglutinin polypeptides, and reagents and methods relating thereto
CA2813685A1 (en) * 2010-10-15 2012-04-19 Josef Weigl Recombinant modified vaccinia virus ankara influenza vaccine
EP2651439B1 (en) 2010-12-17 2018-09-19 Globeimmune, Inc. Compositions and methods for the treatment or prevention of human adenovirus-36 infection
CN103458922B (en) * 2011-01-31 2017-10-03 纳米医疗公司 Recombinant viral vector and method of the induction to the heterologous hypotype immune response of influenza A virus
CA2827150C (en) 2011-02-12 2018-09-11 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis b infection
RU2690180C2 (en) 2011-03-17 2019-05-31 Глоубиммьюн, Инк. Yeast-based immunotherapeutic compositions with brachyury
CN103732249A (en) * 2011-05-23 2014-04-16 威斯特解剖及生物研究所 Influenza vaccines containing modified adenovirus vectors
SG195383A1 (en) 2011-06-14 2013-12-30 Globeimmune Inc Yeast-based compositions and methods for the treatment or prevention of hepatitis delta virus infection
AU2012273039B2 (en) * 2011-06-20 2016-12-01 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Computationally optimized broadly reactive antigens for H1N1 influenza
CN104024429B (en) 2011-08-17 2019-06-04 全球免疫股份有限公司 Yeast-MUC1 immunotherapeutic composition and application thereof
ES2525205T3 (en) * 2011-11-09 2014-12-18 Werner Lubitz Vaccine for use in tumor immunotherapy
DE102011121069A1 (en) 2011-12-13 2013-06-13 Martin-Luther-Universität Halle-Wittenberg Vaccination by recombinant yeast by generating a protective humoral immune response against defined antigens
JP6355630B2 (en) 2012-06-26 2018-07-11 バイオデシックス・インコーポレイテッドＢｉｏｄｅｓｉｘ Ｉｎｃ Method for selecting or excluding cancer patients to be treated with a therapeutic agent for generating an immune response using mass spectra
US20140065173A1 (en) 2012-09-06 2014-03-06 Orbis Health Solutions Llc Tumor lysate loaded particles
JP5954079B2 (en) 2012-09-25 2016-07-20 ソニー株式会社 Culture observation apparatus and culture observation method
US11105802B2 (en) * 2012-12-10 2021-08-31 Seattle Children's Hospital Cell-free biofragment compositions and related systems, devices, and methods
AU2014235120B2 (en) * 2013-03-15 2017-01-05 The Trustees Of The University Of Pennsylvania Vaccines having an antigen and interleukin-23 as an adjuvant
TWI674108B (en) 2013-03-19 2019-10-11 美商環球免疫公司 Yeast-based immunotherapy for chordoma
TWI728239B (en) * 2013-03-26 2021-05-21 美商環球免疫公司 Compositions and methods for the treatment or prevention of human immunodeficiency virus infection
JP2014210747A (en) * 2013-04-19 2014-11-13 アンジェスＭｇ株式会社 Oral vaccine having improved cell-mediated immunity induction potency
WO2015031778A2 (en) 2013-08-30 2015-03-05 Globeimmune, Inc. Compositions and methods for the treatment or prevention of tuberculosis
US10835595B2 (en) 2014-01-06 2020-11-17 The Trustees Of The University Of Pennsylvania PD1 and PDL1 antibodies and vaccine combinations and use of same for immunotherapy
EP3932392A1 (en) 2014-03-05 2022-01-05 Orbis Health Solutions LLC Vaccine delivery systems using yeast cell wall particles
AU2015243256B2 (en) 2014-04-11 2020-11-05 Globeimmune, Inc. Yeast-based immunotherapy and type I interferon sensitivity
CN105233302B (en) * 2014-07-10 2018-10-19 中国人民解放军军事医学科学院生物工程研究所 A kind of preparation method of influenza hemagglutinin glycopolypeptide multimer object nano particle
AU2016205208A1 (en) 2015-01-09 2017-07-06 Etubics Corporation Methods and compositions for ebola virus vaccination
US11020470B2 (en) * 2015-04-13 2021-06-01 The Regents Of The University Of Michigan Virus-like particles
WO2017023840A1 (en) 2015-08-03 2017-02-09 Globeimmune, Inc. Modified yeast-brachyury immunotherapeutic compositions
AU2016304853C1 (en) * 2015-08-11 2023-03-16 Orbis Health Solutions Llc Bacterial and viral vaccine strategy
GB2552441A (en) * 2015-10-22 2018-01-31 Royal Veterinary College Methods
EP3195878A1 (en) 2016-01-22 2017-07-26 Werner Lubitz Bacterial ghosts for the treatment of cancer
KR20180117227A (en) 2016-03-24 2018-10-26 난트셀, 인크. Sequences and sequence arrangements for neo-epitope presentation
IL314202A (en) 2017-04-24 2024-09-01 Nantcell Inc Targeted neoepitope vectors and methods therefor
AU2018388102A1 (en) 2017-12-21 2020-07-16 Green Biomed, Inc. Cross-immunizing antigen vaccine and method for preparation thereof
DE102017012109A1 (en) * 2017-12-27 2019-06-27 Martin-Luther-Universität Halle-Wittenberg Optimized host / vector system for the generation of protective mono- and multivalent subunit vaccines based on the yeast Kluyveromyces lactis
EP3793576A4 (en) * 2018-05-15 2022-04-06 Globeimmune, Inc. Lysates of recombinant yeast for inducing cellular immune responses
JP7320601B2 (en) * 2018-09-11 2023-08-03 上▲海▼市公共▲衛▼生▲臨▼床中心 Broad-spectrum anti-influenza vaccine immunogen and its use
US20210290708A1 (en) 2018-09-21 2021-09-23 Nantcell, Inc. Methods and compositions for modulating myeloid-derived suppressor cells
JP2022532922A (en) * 2019-05-21 2022-07-20 エスペロバックス インコーポレイティド Yeast-based oral vaccination
CN116113424A (en) * 2020-02-11 2023-05-12 赛托纳斯治疗公司 Fast vaccine platform
US11857620B2 (en) 2020-03-11 2024-01-02 Immunitybio, Inc. Method of inducing immunity against SARS-CoV-2 using spike (s) and nucleocapsid (N)-ETSD immunogens delivered by a replication-defective adenovirus
US20210284716A1 (en) 2020-03-11 2021-09-16 Immunitybio, Inc. ACE2-Fc Trap
WO2021211691A1 (en) 2020-04-14 2021-10-21 Immunitybio, Inc. Yeast lysate covid-19 vaccine

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830463A (en) 1993-07-07 1998-11-03 University Technology Corporation Yeast-based delivery vehicles
US5413914A (en) 1993-07-07 1995-05-09 The Regents Of The University Of Colorado Yeast assay to identify inhibitors of dibasic amino acid processing endoproteases
US5962298A (en) * 1994-01-11 1999-10-05 Vlaams Interuniversitair Instituut Voor Biotechnologie Influenza vaccine
US5691189A (en) * 1994-01-19 1997-11-25 Bristol-Myers Squibb Company Saccharomyces cerevisiae expressing M2 protein of influenza A virus
US6696251B1 (en) * 1996-05-31 2004-02-24 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US20020044948A1 (en) * 2000-03-15 2002-04-18 Samir Khleif Methods and compositions for co-stimulation of immunological responses to peptide antigens
ATE376059T1 (en) * 2000-06-23 2007-11-15 Wyeth Corp ASSEMBLY OF WILD-TYPE AND CHIMERIC INFLUENZA VIRUS-LIKE PARTICLES (VLPS)
WO2002039951A2 (en) 2000-11-15 2002-05-23 Globe Immune, Inc. Yeast-dentritic cell vaccines and uses thereof
US20030008000A1 (en) * 2001-03-08 2003-01-09 Wong Jonathan P. DNA vaccine using liposome-encapsulated plasmid DNA encoding for hemagglutinin protein of influenza virus
US20030202982A1 (en) * 2001-08-15 2003-10-30 Birkett Ashley J. Influenza immunogen and vaccine
US7439042B2 (en) * 2002-12-16 2008-10-21 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
KR101241272B1 (en) * 2002-12-16 2013-03-15 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 Yeast-based vaccines as immunotherapy
US8592197B2 (en) * 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
US20060024670A1 (en) * 2004-05-18 2006-02-02 Luke Catherine J Influenza virus vaccine composition and methods of use
WO2006032039A2 (en) * 2004-09-17 2006-03-23 University Of Massachusetts Compositions and their uses for lysosomal enzyme deficiencies
CN101405026B (en) * 2006-02-02 2015-04-22 全球免疫股份有限公司 Yeast-based vaccine for inducing an immune response

Also Published As

Publication number Publication date
WO2007092792A2 (en) 2007-08-16
KR20080089671A (en) 2008-10-07
AU2007212076A1 (en) 2007-08-16
CN104826102A (en) 2015-08-12
CN101405026B (en) 2015-04-22
KR101492524B1 (en) 2015-02-12
MX2008009929A (en) 2008-10-01
EP1988919A4 (en) 2009-06-10
TW200806316A (en) 2008-02-01
CN101405026A (en) 2009-04-08
EP1988919A2 (en) 2008-11-12
JP5198290B2 (en) 2013-05-15
CA2638815A1 (en) 2007-08-16
KR20140029551A (en) 2014-03-10
SG10201402236VA (en) 2014-08-28
EP2468296A2 (en) 2012-06-27
IL193196A0 (en) 2011-08-01
IL193196A (en) 2015-01-29
AU2007212076B2 (en) 2012-10-18
JP2013075899A (en) 2013-04-25
EP2468296A3 (en) 2013-12-04
IL232518A0 (en) 2014-06-30
US7736642B2 (en) 2010-06-15
WO2007092792A3 (en) 2008-02-28
BRPI0706913A2 (en) 2011-04-12
SG169375A1 (en) 2011-03-30
JP2009528987A (en) 2009-08-13
TW201412329A (en) 2014-04-01
US20100196411A1 (en) 2010-08-05
JP2015038147A (en) 2015-02-26
US20080003239A1 (en) 2008-01-03

Similar Documents

Publication Publication Date Title
IN2014DN08830A (en)
WO2007024941A3 (en) Polyvalent vaccine
WO2010019262A3 (en) Polyvalent vaccine
AU2009326524A8 (en) Use of Flt3 ligand for strengthening immune responses in RNA immunization
MXPA05013973A (en) Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes.
PH12014501835A1 (en) Novel adjuvant compositions
WO2007120673A3 (en) Immunogenic wt-1 peptides and methods of use thereof
TW200719910A (en) C. perfringens alpha toxoid vaccine
SG158154A1 (en) Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes
WO2006068663A3 (en) Vaccine compositions for treating coronavirus infection
MX2010012999A (en) Meningococcal multivalent native outer membrane vesicle vaccine, methods of making and use thereof.
WO2016019134A8 (en) Flagellin-based agents and uses including effective vaccination
WO2006113214A3 (en) Vaccine against pandemic strains of influenza viruses
WO2008148057A3 (en) Cationic lipids compositions and methods for enhancing immune responses to vaccines
PH12015501637A1 (en) Inactivated dengue virus vaccine with aluminium-free adjuvant
IN2014DN09791A (en)
CA2763359C (en) New human rotavirus strains and vaccines
WO2009135199A3 (en) Vaccine compositions and methods
MX2016001695A (en) Combination immunogenic compositions.
AU2007272785A8 (en) Methods to elicit, enhance and sustain immune responses against MHC class-I restricted epitopes, for prophylactic or therapeutic purposes
WO2011074006A3 (en) Vaccine composition
WO2007120603A3 (en) Immunogenic bcr-abl peptides and methods of use thereof
WO2012103444A3 (en) Immunogenic compositions and reagents for preparing
WO2010080188A3 (en) Epitope targeted anthrax vaccine
WO2007028985A3 (en) Adjuvanted vaccine